Cargando…
Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
Lung cancer survivors are at risk of developing second primary cancers (SPCs). Although some risk factors for the development of SPCs have been addressed, their impacts have not been clarified. This study, based on Taiwan’s National Health Insurance Research Database (NHIRD), a nationwide database,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457496/ https://www.ncbi.nlm.nih.gov/pubmed/36079152 http://dx.doi.org/10.3390/jcm11175222 |
_version_ | 1784786069751857152 |
---|---|
author | Chou, Wen-Ru Shia, Ben-Chang Huang, Yen-Chun Ho, Chieh-Wen Chen, Mingchih |
author_facet | Chou, Wen-Ru Shia, Ben-Chang Huang, Yen-Chun Ho, Chieh-Wen Chen, Mingchih |
author_sort | Chou, Wen-Ru |
collection | PubMed |
description | Lung cancer survivors are at risk of developing second primary cancers (SPCs). Although some risk factors for the development of SPCs have been addressed, their impacts have not been clarified. This study, based on Taiwan’s National Health Insurance Research Database (NHIRD), a nationwide database, was designed to investigate the risk factors for SPCs in patients with initial lung cancer and identify the impacts of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment on the development of SPCs. In this study, 37,954 individuals were included, of whom 2819 had SPCs. These patients were further divided into the second primary lung cancers (SPLC) and second primary extrapulmonary cancer (SPEC) groups. Among the patients with lung cancer without SPCs, those aged <65 years accounted for 53.15%. Patients aged ≥65 years accounted for 40.18% and 53.24% in the SPLC and SPEC groups, respectively. Females accounted for 50.3% of patients without SPC, 54% of the SPLC group, and 44.3% of the SPEC group. Univariate and multivariate Cox proportional hazard models showed increased hazard ratios for smoking, hypertension, and diabetes mellitus, and lower HRs for surgery, chemotherapy, radiotherapy, and TKIs. Patients undergoing surgery, chemotherapy, and radiotherapy were associated with a lower risk of SPCs. Treatment with EGFR TKIs was a significant and independent factor associated with lower incidence of SPCs. This study may encourage researchers to establish predictive models based on our results to assess the risk factors for SPCs, and therefore, early screening and intervention could be applied, and the SPCs-related mortality and relevant medical costs could be reduced. |
format | Online Article Text |
id | pubmed-9457496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94574962022-09-09 Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers Chou, Wen-Ru Shia, Ben-Chang Huang, Yen-Chun Ho, Chieh-Wen Chen, Mingchih J Clin Med Article Lung cancer survivors are at risk of developing second primary cancers (SPCs). Although some risk factors for the development of SPCs have been addressed, their impacts have not been clarified. This study, based on Taiwan’s National Health Insurance Research Database (NHIRD), a nationwide database, was designed to investigate the risk factors for SPCs in patients with initial lung cancer and identify the impacts of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment on the development of SPCs. In this study, 37,954 individuals were included, of whom 2819 had SPCs. These patients were further divided into the second primary lung cancers (SPLC) and second primary extrapulmonary cancer (SPEC) groups. Among the patients with lung cancer without SPCs, those aged <65 years accounted for 53.15%. Patients aged ≥65 years accounted for 40.18% and 53.24% in the SPLC and SPEC groups, respectively. Females accounted for 50.3% of patients without SPC, 54% of the SPLC group, and 44.3% of the SPEC group. Univariate and multivariate Cox proportional hazard models showed increased hazard ratios for smoking, hypertension, and diabetes mellitus, and lower HRs for surgery, chemotherapy, radiotherapy, and TKIs. Patients undergoing surgery, chemotherapy, and radiotherapy were associated with a lower risk of SPCs. Treatment with EGFR TKIs was a significant and independent factor associated with lower incidence of SPCs. This study may encourage researchers to establish predictive models based on our results to assess the risk factors for SPCs, and therefore, early screening and intervention could be applied, and the SPCs-related mortality and relevant medical costs could be reduced. MDPI 2022-09-04 /pmc/articles/PMC9457496/ /pubmed/36079152 http://dx.doi.org/10.3390/jcm11175222 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chou, Wen-Ru Shia, Ben-Chang Huang, Yen-Chun Ho, Chieh-Wen Chen, Mingchih Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers |
title | Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers |
title_full | Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers |
title_fullStr | Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers |
title_full_unstemmed | Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers |
title_short | Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers |
title_sort | treating with epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) accompanying lower incidence of second primary cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457496/ https://www.ncbi.nlm.nih.gov/pubmed/36079152 http://dx.doi.org/10.3390/jcm11175222 |
work_keys_str_mv | AT chouwenru treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers AT shiabenchang treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers AT huangyenchun treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers AT hochiehwen treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers AT chenmingchih treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers |